The goal of this clinical trial is to help prevent the development of type 2 diabetes (T2D) in adults who are at risk. The study will test a digital intervention called VA|PREVENTION, a web application designed to support and promote healthy behaviour changes known has T2D risk factors, such as physical activity, diet, and sedentary behaviuor. The main questions this study will explore are:• Is the VA|PREVENTION web app, which includes a virtual human coach, effective in preventing type 2 diabetes?• Can the VA|PREVENTION web app be successfully implemented in real-world settings?• Is the VA|PREVENTION web app cost-effective?• Is it safe for participants to use?To answer these questions, the study team will compare the VA|PREVENTION web app to an openly available guidebook that provides standard information about preventing type 2 diabetes.Participants will complete the following activities:
* Participants will be randomly assigned to one of two groups: one group will use the VA|PREVENTION app, while the other group will have access to an openly accessible guidebook on T2D prevention.
* Participants will be in the study for 10 months.
* Participants will be assessed at the start of the study (baseline), and again at 4 months and 10 months.
* Assessments will include body measurements (such as weight, height, and waist circumference), physical activity levels, and responses to questionnaires.

开始日期2025-06-03

申办/合作机构

Universidade Nova de Lisboa

NCT05593835

/ Not yet recruitingN/A

Protocol for a Cluster Randomised Trial of a Goal-Oriented Care Approach for Multimorbidity Patients Supported by a Digital Platform

This study aims to assess whether the use of the METHIS digital platform using a patient-centered approach contributes to an improvement in the quality of life, mental health and physical activity of patients with multimorbidity followed up in Primary Health Care. Practices will be randomly allocated between: providing access to consultations through the METHIS platform (intervention) or following patients by the traditional method (control). They will complete questionnaires on quality of life, mental health and report the number of steps taken, at the beginning and end of the study.

开始日期2025-06-01

申办/合作机构

Universidade Nova de Lisboa

[+2]

NCT06794515

/ Not yet recruitingN/A

Metabolic Effects of cGMP: From Amino Acid Absorption Kinetics to Appetite Modulation

Phenylketonuria is an inborn error of phenylalanine metabolism. Although the phenylalanine-restricted diet is recognized as the mainstay of therapy, little is known about the impact of protein substitutes on the metabolism of patients with phenylketonuria.
Therefore, the aim of this project is to study the impact of acute ingestion of casein glycomacropeptide supplemented with amino acids (cCGMP-AAs) alone or in combination with two different meals on amino acid absorption kinetics, glycaemic and insulinemic response, and on acute markers of appetite control.
The main findings of this project will bring new insights into the dietary management of these patients, which may lead to improvements in protein substitutes formulations.

开始日期2025-02-03

申办/合作机构

Universidade Nova de Lisboa

100 项与 Universidade Nova de Lisboa 相关的临床结果

登录后查看更多信息

0 项与 Universidade Nova de Lisboa 相关的专利（医药）

登录后查看更多信息

15,933

项与 Universidade Nova de Lisboa 相关的文献（医药）

2026-02-01·Intensive and Critical Care Nursing

Biomarkers in sepsis: Less is more? Yes, it is

Article

作者: Póvoa, Pedro ; Guerreiro, Gonçalo

2026-02-01·IMMUNOLOGY LETTERS

The essential integration of sex and gender in immunological research

Review

作者: Pecht, Tal ; Ingersoll, Molly ; Consiglio, Camila ; Darragh, Duffy ; Altfeld, Marcus ; Shay, Tal ; Soares, Helena ; O'Farrelly, Cliona

2026-01-01·THERIOGENOLOGY

Beneficial effect of AntiOxBEN2, a mitochondria-directed antioxidant, on maturation of bovine oocytes: Analysis of bioenergetics pathways and embryo production

Article

作者: Jorge, Joana ; Cagide, Fernando ; Ferreira, Filipa ; Pereira, Rosa M L N ; Oliveira, Paulo J ; Teixeira, Camila ; Gonçalves, Ana Cristina ; Borges, Fernanda ; Lidon, Fernando ; Teixeira, José ; Prates, José A M

Oxidative stress during in vitro maturation of oocytes impairs mitochondrial function and reduces developmental competence. We evaluated the potential of AntiOxBEN₂, a novel triphenylphosphonium-conjugated antioxidant, to enhance bovine oocyte maturation and early embryo development. Cumulus-oocyte complexes were matured for 22h in medium supplemented with 0, 10, 20, 50, or 100 μM AntiOxBEN₂. Nuclear maturation rates, cleavage and blastocyst formation were assessed after in vitro fertilization, while bioenergetic parameters (lactate production, oxygen consumption rate, intracellular ATP, and reactive oxygen species (ROS), transcripts for antioxidant defense-related genes (Nfe2l2/Nqo1), and mtND5 gene copy number, as an indirect measure of mitochondrial DNA copy number, were measured in mature oocytes. AntiOxBEN₂ improved nuclear maturation in a dose-dependent manner (p < 0.05) and maximized cleavage rate at 10 μM (79.4 ± 2.5 % versus 67.7 ± 2.7 % in control; p ≤ 0.01). At this concentration, mtND5 copy number also increased significantly (p < 0.05), whereas higher doses (50-100 μM) delayed meiosis and elevated lactate without affecting ATP, ROS, or oxygen consumption. No treatment altered Nfe2l2 or Nqo1 transcript levels. These findings indicate that 10 μM AntiOxBEN₂ optimizes mitochondrial biogenesis and enhances early embryo cleavage, supporting its inclusion in maturation media as a strategy to improve assisted reproductive technologies (ART).

项与 Universidade Nova de Lisboa 相关的新闻（医药）

2021-02-08

·BioSpace

Rute Fernandes Appointed General Manager of Takeda Canada

TORONTO, Feb. 8, 2021 /CNW/ - Takeda Canada Inc. ("Takeda Canada") is pleased to announce the appointment of Rute Fernandes as its new General Manager to lead the Canadian operations of Japan's largest pharmaceutical company. Ms. Fernandes has held a number of executive roles in business development, commercial strategy operations, and country management over her 22-year career in the pharmaceutical industry. Most recently, she served as Takeda's Group Vice-President and Head of Rare Disease Franchise for Europe and Canada, responsible for a portfolio of more than 15 brands across three disease areas—namely Rare Metabolic Disorders, Rare Hematology, and Rare Hereditary Angioedema and Transplants—in a total of 38 countries. "Rute is an inspiring leader who has acquired broad experience in senior management roles and a deep understanding of rare diseases internationally," said Giles Platford, President of the Europe and Canada Business Unit at Takeda. "Canada is a critical market for Takeda's global operations and I am confident that under Rute's leadership, Takeda will strengthen our position as a leading biopharmaceutical company in the country, delivering highly innovative medicines and transformative care to Canadians." Takeda is a global, values-based, R&D-driven biopharmaceutical company with an unwavering commitment to bringing Better Health and a Brighter Future to people around the world. Established in Canada in 2009, Takeda is one of the fastest-growing pharmaceutical companies in Canada and a leader in the treatment of rare diseases. "I am delighted to have been selected to lead Takeda Canada and work alongside the many talented individuals that make up the Canadian Team," said Rute Fernandes. "This is an important time for our industry in Canada, and I look forward to ensuring sustainable access to innovative medicines for Canadians who need them most." Ms. Fernandes holds a Master's in Economics from the Nova School of Business & Economics and an MBA from HEC Lausanne. About Takeda Canada Inc. Takeda Canada Inc. is the Canadian marketing and sales organization of Takeda Pharmaceutical Company Limited, headquartered in Japan. Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Rare Diseases and Neuroscience. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. Additional information about Takeda Canada is available at SOURCE Takeda Canada, Inc. Company Codes: NYSE:TAK, Tokyo:4502

疫苗

100 项与 Universidade Nova de Lisboa 相关的药物交易

登录后查看更多信息

100 项与 Universidade Nova de Lisboa 相关的转化医学

登录后查看更多信息